07/02/2026
šØ Mounjaro Adverse Reactions Explode Over 300% in 2025ā71 Deaths LinkedāWhile GLP-1 Drugs Generate Tens of Billions for Pharma
New numbers released by the UKās Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme show a sharp and troubling rise in problems tied to Mounjaro (tirzepatide) and similar GLP-1 drugs.
In 2025 alone:
⢠40,245 reported adverse reactionsāmore than 300% higher than the year before
⢠6,755 classified as serious
⢠71 linked to deaths
For comparison, 2024 had roughly 9,153 reports and 13 fatalities.
People are reporting brutal side effects:
⢠intense, stabbing abdominal pain that wonāt let up,
⢠relentless vomiting and diarrhea,
acute pancreatitis,
⢠gastrointestinal perforations,
blood clots,
⢠and in some cases a terrifying slide into septic shock and multiple organ failure.
One case that stands out: a 58-year-old nurse died from acute pancreatitis, septic shock, and multi-organ failure after receiving only two low-dose injections.
The death certificate directly pointed to Mounjaro as a contributing cause.
Drugs like Mounjaro, Ozempic, Wegovy, and the rest of the GLP-1 class are being sold hard as game-changing solutions for weight loss and diabetes.
Behind the before-and-after photos and influencer posts, the manufacturers are pulling in tens of billions each yearāturning obesity into one of the most profitable medical markets ever created.
Officials still say the benefits outweigh the risks when used as approved.
But with reports climbing this fast and people dying, that line is getting harder to accept at face value.
These injections are powerful.
They change how the body works at a fundamental level, and the serious complications seem to be showing up far more often than most patients are warned about.
People deserve to know the full picture before they sign up for something this strong.
š https://www.dailymail.co.uk/health/article-15523195/amp/Adverse-reactions-Mounjaro-increased-300-cent-2025-fat-jab-linked-71-deaths.html